Correction to: Patterns of Use, Efficacy, and Safety of Treatment Options for Patients with Graves' Disease: A Nationwide Population-Based Study by Brito JP, Payne S, Singh Ospina N, Rodriguez-Gutierrez R, Maraka S, Sangaralingham LR, Iñiguez-Ariza NM, Montori VM, and Stan MN Thyroid 2020;30:357-364. DOI: 10.1089/thy.2019.0132.

Abstract

ThyroidVol. 30, No. 6 CorrectionOpen AccessCorrection to: Patterns of Use, Efficacy, and Safety of Treatment Options for Patients with Graves' Disease: A Nationwide Population-Based Study by Brito JP et al. Thyroid 2020;30:357–364. DOI: 10.1089/thy.2019.0132is erratum ofPatterns of Use, Efficacy, and Safety of Treatment Options for Patients with Graves' Disease: A Nationwide Population-Based StudyPublished Online:5 Jun 2020https://doi.org/10.1089/thy.2019.0132.correxAboutSectionsPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail In the March 2020 issue of Thyroid (vol. 30, no. 3; pp. 357–364) the article entitled “Patterns of Use, Efficacy, and Safety of Treatment Options for Patients with Graves' Disease: A Nationwide Population-Based Study” by Brito et al. requires correction.In the Treatment section “RAI (n = 1549)” of Table 3, the number of patients and percentage of patients have been updated, though the main text was correct.The original table reads:Table 3. Frequency of Adverse EffectsTreatmentComplicationsNo. of patients% of patientsMethimazole (n = 2443)Agranulocytosis00Aplastic anemia00Hepatitis, unspecified (includes drug induced)311.3Rash and other nonspecific skin eruption923.8New Graves' ophthalmopathy1777All methimazole complicationsa29912Propylthiouracil (n = 374)Aplastic anemia00Drug-induced cholestasis00Rash and other nonspecific skin eruption184.8ANCA vasculitis00New Graves' ophthalmopathy266.9All propylthiouracil complicationb4612.3RAI (n = 1549)Radiation-induced thyroiditis130.8New Graves' ophthalmopathy1509.6All RAI complication16110.3Total thyroidectomy (n = 177)Hypoparathyroidism4625.9All total thyroidectomy complicationsc5531Partial surgery (n = 118)All partial surgery complicationsd1512.7Given to OptumLabs report policies, adverse events between 0 and 10 events could only be described as composite. This composite has been added to the total frequency of complication for each treatment modality.aInclude acute and subacute necrosis of liver, drug-induced cholestasis, and anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis.bInclude agranulocytosis, acute and subacute necrosis of liver, hepatitis, unspecified (includes drug induced).cInclude hemorrhage, seroma, infection, vocal cord paralysis, and dysphonia.dInclude hemorrhage, seroma, infection, vocal cord paralysis, dysphonia, and hypoparathyroidism.The Table has been revised to:Table 3. Frequency of Adverse EffectsTreatmentComplicationsNo. of patients% of patientsMethimazole (n = 2443)Agranulocytosis00Aplastic anemia00Hepatitis, unspecified (includes drug induced)311.3Rash and other nonspecific skin eruption923.8New Graves' ophthalmopathy1777All methimazole complicationsa29912Propylthiouracil (n = 374)Aplastic anemia00Drug-induced cholestasis00Rash and other nonspecific skin eruption184.8ANCA vasculitis00New Graves' ophthalmopathy266.9All propylthiouracil complicationb4612.3RAI (n = 1549)Radiation-induced thyroiditis130.84New Graves' ophthalmopathy895.75All RAI complication1006.46Total thyroidectomy (n = 177)Hypoparathyroidism4625.9All total thyroidectomy complicationsc5531Partial surgery (n = 118)All partial surgery complicationsd1512.7Given to OptumLabs report policies, adverse events between 0 and 10 events could only be described as composite. This composite has been added to the total frequency of complication for each treatment modality.aIncludes acute and subacute necrosis of liver, drug-induced cholestasis, and anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis.bIncludes agranulocytosis, acute and subacute necrosis of liver, hepatitis, unspecified (includes drug induced).cIncludes hemorrhage, seroma, infection, vocal cord paralysis, and dysphonia.dIncludes hemorrhage, seroma, infection, vocal cord paralysis, dysphonia, and hypoparathyroidism.The online version has been corrected to reflect this. The authors apologize for these errors.FiguresReferencesRelatedDetailsRelated articlesPatterns of Use, Efficacy, and Safety of Treatment Options for Patients with Graves' Disease: A Nationwide Population-Based Study11 Mar 2020Thyroid Volume 30Issue 6Jun 2020 InformationCopyright 2020, Mary Ann Liebert, Inc., publishersTo cite this article:Thyroid.Jun 2020.938-938.http://doi.org/10.1089/thy.2019.0132.correxPublished in Volume: 30 Issue 6: June 5, 2020PDF download